Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
Phase III Multicentric Study Evaluating the Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
This PHASE3 trial investigates Vascular Malformations and is currently actively recruiting participants. Cliniques universitaires Saint-Luc- Université Catholique de Louvain leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2023 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
For direct contact, visit the study record on ClinicalTrials.gov .